🇺🇸 FDA

Company profile · Sponsor

CAPRICOR

CAPRICOR THERAPEUTICS, INC.

CAPR · NYSE pharma SAN DIEGO, CA, USA
Pipeline
8
Drugs
0
Patents
8

Quick answer

CAPRICOR (CAPR) is a pharma company. headquartered in SAN DIEGO, CA, USA. listed on NYSE. NovaPharmaNews links 8 pipeline programs, 0 drugs, and 8 patents to this profile..

Company facts

Ticker CAPR
Exchange NYSE
Company type pharma
Headquarters SAN DIEGO, CA, USA
SEC CIK 0001133869

Pipeline (8)

Search pipeline →

  1. Deramiocel (CAP-1002)

    CAPRICOR

    Muscular Dystrophies

    phase 3 mab active

    1 trial

  2. Allogeneic Cardiosphere-Derived Cells (CAP-1002)

    CAPRICOR

    Duchenne Muscular Dystrophy

    phase 2 small molecule completed

    2 trials

  3. CAP-1002

    CAPRICOR

    Muscular Dystrophies

    phase 2 mab completed

    1 trial

  4. CAP-1002

    CAPRICOR

    Covid19

    phase 2 mab completed

    1 trial

  5. CAP-1002 Allogeneic Cardiosphere-Derived Cells

    CAPRICOR

    Myocardial Infarction

    phase 2 mab terminated

    1 trial

  6. Cenderitide

    CAPRICOR

    Heart Failure

    phase 2 small molecule completed

    2 trials

  7. Deramiocel (CAP-1002)

    CAPRICOR

    Duchenne Muscular Dystrophy

    phase 2 mab active

    1 trial

  8. Allogeneic Cardiosphere-Derived Cells (CDCs)

    CAPRICOR

    Dilated Cardiomyopathy (DCM)

    phase 1 mab active

    1 trial

Patents (8)

Search patents →

  1. US 11801268

    Methods of treating ocular inflammation and chemical injuries of the eye with extracellular vesicles

    Expires Mon Oct 26 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 11759482

    Methods and compositions for treating skeletal muscular dystrophy

    Expires Mon Sep 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 10695293

    Method of preventing or treating radiation-induced dermatitis with extracellular vesicles

    Expires Mon Jun 25 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 10369173

    Optimized methods for generation of cardiac stem cells from cardiac tissue and their use in cardiac therapy

    Expires Mon Aug 01 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 9884076

    Optimized methods for generation of cardiac stem cells from cardiac tissue and their use in cardiac therapy

    Expires Mon Feb 01 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 9623085

    Chimeric natriuretic peptide compositions and methods of preparation

    Expires Mon Apr 13 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 9616107

    Therapy for kidney disease and/or heart failure

    Expires Mon Apr 06 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 9314507

    Methods of treatment of heart failure with natriuretic peptides

    Expires Mon Apr 14 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is CAPRICOR?

CAPRICOR (CAPR) is a pharma company. headquartered in SAN DIEGO, CA, USA. listed on NYSE. NovaPharmaNews links 8 pipeline programs, 0 drugs, and 8 patents to this profile..

What pipeline programs does CAPRICOR sponsor?

We track 8 ClinicalTrials.gov-linked programs for CAPRICOR, including Deramiocel (CAP-1002) and 7 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does CAPRICOR company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.